BIIB vs PCVX
Biogen vs Vaxcyte, Inc. — AI-powered side-by-side comparison
VS
PCVX
Vaxcyte, Inc.
70
Buy
| Metric | BIIB | PCVX |
|---|
| AI Score |
70
|
70
|
| Price |
$209.75
|
$58.08
|
| P/E Ratio |
36.94×
|
-7.60×
|
| ROE |
7.1%
|
-28.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
67.7%
|
0.0%
|
| Debt / Equity |
0.44×
|
0.04×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
60.9
|
54.9
|
| Beta |
0.162
|
1.21
|
| Expected Upside |
+4.3%
|
+6.2%
|
AI Committee View
Current Innellis committee reasoning for BIIB versus PCVX.
The committee scores are tied.
BIIB and PCVX both score 70/100.
BIIB Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is growth rate is decelerating quarter over quarter -- the trend line matters more than the level. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
PCVX Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -37.6% -- cheap may mean cheap for a reason — Value